Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
We compare expense ratios across dividend growth ETFs to identify the lowest-cost options for long-term investing.
28,176 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Florida’s housing market finds footing in late May 2026 as pending sales rise and inventory stabilizes. Sellers face ...
MicroStrategy's crypto treasury, dubbed Strategy, remains substantially underwater as Saylor signals another bitcoin ...
Investors are buzzing about The Metals Company as a potential new source of critical minerals. This article weighs th...
Universal Corp misses EPS and swings to a loss in the third quarter, triggering a double-digit stock drop. Analysts f...
SanDisk announced a $1 billion strategic equity investment in Nanya Technology, prompting a roughly 6% share decline ...
Wix announces a 20% workforce reduction tied to AI and currency headwinds, as an MIT professor contends the move mirr...
Ripple wins preliminary approval to operate under MiCA in Luxembourg, but the path to a full MiCA license is far from...
Korea’s rapid AI-driven swings in key chip names are starting the day for traders around the world. The Kospi’s volat...
The FAA has halted all JetBlue flights at the airline’s request, triggering widespread travel disruption and a swift ...
Brokerages launch pilots that allow 13-year-olds to trade stocks with limited parental approval, prompting wide-rangi...
A consortium led by Barry Diller has proposed a $12.4 billion bid to take MGM Resorts private, a move that could resh...